Please assess the completion status of the following clinical trial:

Trial Title: IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and female greater than 18 years of age~2. Positive stool C. difficile cytotoxin assay and/or biopsy evidence of Pseudomembranous Colitis (PMC) at onset of illness~3. Current history of severe, relapsing CDAD or Current history of severe, refractory CDAD~4. A score of 6 or 7 on the C.Diff Severity and Prognosis Score (CDSPS) scale27,28,29,30 OR failure to respond (as identified by a score of 4 or more on the CDSPS scale below) to any of the following: a 4-day or more course of oral or IV metronidazole 500 mg po TID or QID; or to a 4-day course of oral vancomycin 125-500 mg po Q6 hours; or to a 4-day course of vancomycin enemas; or failure to respond to a 4-day course of combination therapy of oral vancomycin 125-500 mg po Q6 hours and IV metronidazole 500mg IV Q8 or Q6 hours and/or vancomycin enemas.~CDSPS SCALE (each item is scored as one point for a 7 point maximum total)~1. underlying immunosuppression/chronic medical condition~2. altered or depressed mental status as defined by medical chart documentation~3. abdominal pain and/or distention~4. WBC \> 20,000 or \< 1,500 and/or bandemia \> 10%~5. hypoalbuminemia (\<3 mg/dL)~6. ascites (clinically or per CT scan findings per medical chart)~7. abnormal CT scan findings per medical chart -~Exclusion Criteria:~1. Pregnant or lactating women~2. Selective IgA deficiency~3. Hypersensitivity to immune globulin, human albumin, or thimerosal -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IVIG (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).